Related Experiment Video
Updated: Jan 6, 2026
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomas
Vincent Harlay1, Céline Bequet2, Romain Appay3,4
1Neuro-Oncology Department, AP-HM, Aix-Marseille University, University Hospital Timone, 264 Rue Saint Pierre, Marseille, 13005, France. vincent.harlay@ap-hm.fr.
Purpose:
"Biopsy-only" glioblastoma (BO-GB) is an understudied entity associated with a poor outcome for whom quality of life preservation is essential. Our objective was to define and determine the time of autonomy duration in BO-GB and its potential predictive factors.
Methods:
Patients diagnosed with IDH wild-type BO-GB and enrolled in a prospective regional cohort from 2014 to 2017 were analyzed for their clinical features, functional status, histo-molecular profile, neuroimaging findings, and treatment details.
Results:
137 patients were included in the present analysis. Median age at inclusion was 66 years old and median KPS was 70. Median time of autonomy duration was 7.7 months (CI95%: 5.6-9.7). In the radiotherapy - temozolomide subgroup, median time of autonomy duration was 9.1 months (CI95%: 8.1-10.3); in the chemotherapy upfront group, median time of autonomy duration was 5.3 months (CI95%: 3.5-7.1). Autonomy duration was correlated to patient age and overall survival but not with initial functional status. Among the 65 patients with KPS < 70 at baseline, 11 patients (16.9%) restored their autonomy under treatment. Autonomy duration was not different between these 11 patients and the patients with baseline KPS ≥ 70 (p = 0.758).
Conclusion:
Autonomy duration may serve as a surrogate endpoint for overall survival for BO-GB patients and may be included in future clinical trials dedicated to this frail population.
